More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
A new study published in JAMA, which looked at fee-for-service Medicare records from 2013–2023, found that overall participation has trended upward. However, the details paint a complicated picture.
Research that followed patients for more than 13 years suggests increases in ECG PR interval, P‐wave duration and PTFV1 are associated with increased AFib risk in this cohort.
In some cases, researchers noted, CABG may be a better treatment option. The group emphasized that alternative therapies are still needed to improve patient care.
No medications are currently approved for the treatment of nonobstructive hypertrophic cardiomyopathy. Could a new drug from Imbria Pharmaceuticals be the first?
Imagers can now identify vulnerable plaques that were once very challenging to find. The next steps include improving the screening process and determining which lesions need to be treated right away.
